Kyowa Kirin Co., Ltd. KY4.F Stock
Kyowa Kirin Co., Ltd. Price Chart
Kyowa Kirin Co., Ltd. KY4.F Financial and Trading Overview
Kyowa Kirin Co., Ltd. stock price | 16.1 EUR |
Previous Close | 17.3 EUR |
Open | 18.3 EUR |
Bid | 17.5 EUR x 129600 |
Ask | 18.3 EUR x 126400 |
Day's Range | 17.5 - 18.3 EUR |
52 Week Range | 17.3 - 24 EUR |
Volume | 57 EUR |
Avg. Volume | 5 EUR |
Market Cap | 9.67B EUR |
Beta (5Y Monthly) | 0.160536 |
PE Ratio (TTM) | 28.225805 |
EPS (TTM) | 0.66 EUR |
Forward Dividend & Yield | 0.38 (2.13%) |
Ex-Dividend Date | June 29, 2023 |
1y Target Est | N/A |
KY4.F Valuation Measures
Enterprise Value | -337020682240 EUR |
Trailing P/E | 28.225805 |
Forward P/E | 21.341463 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.023925407 |
Price/Book (mrq) | 0.012266164 |
Enterprise Value/Revenue | -0.834 |
Enterprise Value/EBITDA | -3.465 |
Trading Information
Kyowa Kirin Co., Ltd. Stock Price History
Beta (5Y Monthly) | 0.160536 |
52-Week Change | -12.37% |
S&P500 52-Week Change | 20.43% |
52 Week High | 24 EUR |
52 Week Low | 17.3 EUR |
50-Day Moving Average | 19.27 EUR |
200-Day Moving Average | 20.99 EUR |
KY4.F Share Statistics
Avg. Volume (3 month) | 5 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 537.47M |
Float | 242.44M |
Short Ratio | N/A |
% Held by Insiders | 53.68% |
% Held by Institutions | 20.49% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 51 |
Trailing Annual Dividend Yield | 294.79% |
5 Year Average Dividend Yield | 159.00% |
Payout Ratio | 0.5451 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 12.44% |
Operating Margin (ttm) | 19.43% |
Gross Margin | 79.28% |
EBITDA Margin | 24.06% |
Management Effectiveness
Return on Assets (ttm) | 5.34% |
Return on Equity (ttm) | 6.65% |
Income Statement
Revenue (ttm) | 404.16B EUR |
Revenue Per Share (ttm) | 751.96 EUR |
Quarterly Revenue Growth (yoy) | 6.60% |
Gross Profit (ttm) | 311.46B EUR |
EBITDA | 97.27B EUR |
Net Income Avi to Common (ttm) | 50.3B EUR |
Diluted EPS (ttm) | 0.62 |
Quarterly Earnings Growth (yoy) | -20.39% |
Balance Sheet
Total Cash (mrq) | 346.54B EUR |
Total Cash Per Share (mrq) | 644.68 EUR |
Total Debt (mrq) | 0 EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 5.229 |
Book Value Per Share (mrq) | 1426.689 |
Cash Flow Statement
Operating Cash Flow (ttm) | 69.29B EUR |
Levered Free Cash Flow (ttm) | 34.7B EUR |
Profile of Kyowa Kirin Co., Ltd.
Country | Germany |
State | N/A |
City | Tokyo |
Address | Otemachi Financial City Grand Cube |
ZIP | 100-0004 |
Phone | 81 3 5205 7200 |
Website | https://www.kyowakirin.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 5982 |
Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. It has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.
Q&A For Kyowa Kirin Co., Ltd. Stock
What is a current KY4.F stock price?
Kyowa Kirin Co., Ltd. KY4.F stock price today per share is 16.1 EUR.
How to purchase Kyowa Kirin Co., Ltd. stock?
You can buy KY4.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kyowa Kirin Co., Ltd.?
The stock symbol or ticker of Kyowa Kirin Co., Ltd. is KY4.F.
Which industry does the Kyowa Kirin Co., Ltd. company belong to?
The Kyowa Kirin Co., Ltd. industry is Drug Manufacturers-General.
How many shares does Kyowa Kirin Co., Ltd. have in circulation?
The max supply of Kyowa Kirin Co., Ltd. shares is 542.28M.
What is Kyowa Kirin Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Kyowa Kirin Co., Ltd. PE Ratio is 24.39393800 now.
What was Kyowa Kirin Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Kyowa Kirin Co., Ltd. EPS is 0.66 EUR over the trailing 12 months.
Which sector does the Kyowa Kirin Co., Ltd. company belong to?
The Kyowa Kirin Co., Ltd. sector is Healthcare.